查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678178

2025年全球寡核苷酸治疗市场报告

Oligonucleotide Therapy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

寡核苷酸治疗市场规模预计在未来几年将快速成长。到 2029 年，这一数字将成长至 98.2 亿美元，复合年增长率为 12.3%。预测期内的成长可归因于研发投资、全球市场渗透、治疗领域扩张、缓解疾病策略和监管适应。预测期内的关键趋势包括客製化疗法、递送系统的进步、 RNA干扰(RNAI) 的进步、反义寡核苷酸的创新以及基因编辑技术的整合。

预计预测期内全球癌症患者数量的增加将促进寡核苷酸治疗市场的成长。例如，截至2022年1月，美国癌症协会预测美国将有约190万例新诊断癌症病例，609,360例癌症相关死亡病例，平均每天约有1,670人死亡。全球最常见的癌症是肺癌、摄护腺癌、肠癌和女性乳癌，占所有新癌症病例的 43%。因此，全球癌症发生率的快速成长将在未来几年推动寡核苷酸治疗市场的需求。

政府针对医疗保健研究和开发的倡议预计将推动寡核苷酸治疗市场的成长。这些措施包括不同层级（地方、地区、国家和国际）政府当局为解决具体问题、实现既定目标和为社会带来积极计划而实施的具体行动、计划、政策和项目。各政府机构已启动医疗保健计划，以支持包括寡核苷酸疗法在内的各个方面。 2022年，英国政府承诺向卫生和社会保障部提供2.6亿英镑（2.7065亿美国）的资金，以促进医疗保健研究和製造。该资金由英国商业、工业和战略部和卫生与公众服务部提供，旨在透过新的隐私保护平台和临床研究服务来支持 NHS主导的诊断​​和治疗健康研究。此外，也拨款6,000万英镑（6,360万美国）支持英国生命科学製造业的扩张。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情境 宏观经济情境包括利率、通膨、地缘政治、新冠疫情和市场復苏的影响

第五章 全球成长分析与策略分析框架

  • 全球寡核苷酸治疗学PESTEL分析（政治、社会、科技、环境、法律、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球寡核苷酸治疗市场：成长率分析
  • 全球寡核苷酸治疗市场表现：规模与成长，2019-2024
  • 全球寡核苷酸治疗市场预测：规模与成长，2024-2029 年，2034 年
  • 全球寡核苷酸治疗总目标市场（TAM）

第六章市场区隔

  • 全球寡核苷酸治疗市场类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 反义寡核苷酸
  • 适体
  • 其他类型
  • 全球寡核苷酸治疗市场的应用、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 感染疾病
  • 肿瘤学
  • 神经退化性疾病
  • 心血管疾病
  • 肾臟疾病
  • 其他最终用户
  • 全球寡核苷酸治疗市场（依最终使用者、绩效及预测），2019-2024 年、2024-2029 年及 2034 年
  • 医院
  • 研究机构
  • 全球寡核苷酸治疗市场反义寡核苷酸细分市场，依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • RNA标靶反义寡核苷酸
  • DNA标靶反义寡核苷酸
  • 化学修饰的反义寡核苷酸
  • 全球寡核苷酸治疗市场、适体细分、类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • DNA适体
  • RNA适体
  • 小分子适体
  • 全球寡核苷酸治疗市场及其他细分市场，依类型、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • siRNA（小干扰RNA）
  • miRNA（微型RNA）
  • 脱氧核糖核酸酶和核酶
  • 用于基因编辑的合成寡核苷酸

第七章 区域和国家分析

  • 全球寡核苷酸治疗市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球寡核苷酸治疗市场：依国家/地区、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 寡核苷酸治疗市场：竞争格局
  • 寡核苷酸治疗市场：公司简介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Moderna Inc.
  • Biogen Inc.
  • Jazz Pharmaceuticals plc
  • QIAGEN Company
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Akcea Therapeutics Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Dicerna Pharmaceuticals Inc.
  • SomaGenics Inc.
  • Wave Life Sciences Ltd.
  • Exicure Inc.
  • Avidity Biosciences Inc.
  • Miragen Therapeutics Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年寡核苷酸治疗市场：提供新机会的国家
  • 寡核苷酸治疗市场2029：细分领域带来新机会
  • 寡核苷酸治疗市场2029：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r26811

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.55 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Subsegments:
  • 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
  • 2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
  • 3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; BioNTech SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Oligonucleotide Therapy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
  • 5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)

6. Oligonucleotide Therapy Market Segmentation

  • 6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotide
  • Aptamer
  • Other Types
  • 6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other End-User
  • 6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutes
  • 6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • RNA-Targeted Antisense Oligonucleotides
  • DNA-Targeted Antisense Oligonucleotides
  • Chemically Modified Antisense Oligonucleotides
  • 6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA Aptamers
  • RNA Aptamers
  • Small Molecule Aptamers
  • 6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • siRNA (Small Interfering RNA)
  • miRNA (Micro RNA)
  • DNAzyme And Ribozymes
  • Synthetic Oligonucleotides For Gene Editing

7. Oligonucleotide Therapy Market Regional And Country Analysis

  • 7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

  • 8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oligonucleotide Therapy Market

  • 9.1. China Oligonucleotide Therapy Market Overview
  • 9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oligonucleotide Therapy Market

  • 10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oligonucleotide Therapy Market

  • 11.1. Japan Oligonucleotide Therapy Market Overview
  • 11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oligonucleotide Therapy Market

  • 12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

  • 13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oligonucleotide Therapy Market

  • 14.1. South Korea Oligonucleotide Therapy Market Overview
  • 14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

  • 15.1. Western Europe Oligonucleotide Therapy Market Overview
  • 15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oligonucleotide Therapy Market

  • 16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oligonucleotide Therapy Market

  • 17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oligonucleotide Therapy Market

  • 18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oligonucleotide Therapy Market

  • 19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oligonucleotide Therapy Market

  • 20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

  • 21.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • 21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oligonucleotide Therapy Market

  • 22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oligonucleotide Therapy Market

  • 23.1. North America Oligonucleotide Therapy Market Overview
  • 23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oligonucleotide Therapy Market

  • 24.1. USA Oligonucleotide Therapy Market Overview
  • 24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oligonucleotide Therapy Market

  • 25.1. Canada Oligonucleotide Therapy Market Overview
  • 25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oligonucleotide Therapy Market

  • 26.1. South America Oligonucleotide Therapy Market Overview
  • 26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oligonucleotide Therapy Market

  • 27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oligonucleotide Therapy Market

  • 28.1. Middle East Oligonucleotide Therapy Market Overview
  • 28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oligonucleotide Therapy Market

  • 29.1. Africa Oligonucleotide Therapy Market Overview
  • 29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Oligonucleotide Therapy Market Competitive Landscape
  • 30.2. Oligonucleotide Therapy Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • 31.1. Moderna Inc.
  • 31.2. Biogen Inc.
  • 31.3. Jazz Pharmaceuticals plc
  • 31.4. QIAGEN Company
  • 31.5. Alnylam Pharmaceuticals Inc.
  • 31.6. Sarepta Therapeutics Inc.
  • 31.7. Ionis Pharmaceuticals Inc.
  • 31.8. Akcea Therapeutics Inc.
  • 31.9. Arrowhead Pharmaceuticals Inc.
  • 31.10. Dicerna Pharmaceuticals Inc.
  • 31.11. SomaGenics Inc.
  • 31.12. Wave Life Sciences Ltd.
  • 31.13. Exicure Inc.
  • 31.14. Avidity Biosciences Inc.
  • 31.15. Miragen Therapeutics Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

34. Recent Developments In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

  • 35.1 Oligonucleotide Therapy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oligonucleotide Therapy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oligonucleotide Therapy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer